GLP1R and diabetes mellitus: Our study showed that 39.2% of patients with diabetes were being treated with medications from the newer antidiabetic drug classes (e.g., GLP-1 receptor agonists or SGLT2 inhibitors), which are significantly more expensive than traditional antidiabetic medications (e.g., metformin, sulfonylureas) [6].